

ASX Announcement | 30 June 2022
Visioneering Technologies (ASX:VTI)

Visioneering Technologies, Inc. Welcomes Dr. Allan E. Rubenstein as Independent Director

Atlanta, Georgia, USA, 29 June 2022 (Sydney, 30 June 2022): US-based medical device company and producer of the NaturalVue® Multifocal 1 Day Contact Lenses ('NVMF'), **Visioneering Technologies, Inc (ASX: VTI)** ('Visioneering,' 'VTI' or 'the Company') today announced the appointment of Dr. Allan E. Rubenstein as an independent non-executive director, and the pending retirement of Zita Peach from its Board of Directors.

Dr. Rubenstein will commence his term on 29 June 2022. He is a highly experienced public company board director, a successful entrepreneur, and a respected medical doctor. He served for 29 years on the board of The Cooper Companies, Inc. (NYSE: COO), including as either Chairman or Lead Independent Director for all but two of those years. The Cooper Companies, Inc. is the parent company of CooperVision, one of the largest contact lens companies in the world.

Dr. Rubenstein is a neurologist known for his pioneering work on research and treatment of neurofibromatosis ("NF"), a rare genetic disorder, and has become an expert due to his commercial interests in genomics, ocular conditions and treatments, medical devices, and women's health. He started the first multidisciplinary clinic devoted to NF in the world at Mount Sinai School of Medicine, which over the years became the model for more than 100 other NF clinics in the U.S., Europe, and South America.

Dr. Rubenstein achieved success early in his career by founding, growing, and selling a mobile CT and MRI scanning company in New York City. After growing the company both organically and through acquisition to serve multiple states, he sold the business. He then founded and served as CEO of NexGenix Pharmaceuticals, which developed drugs for cancer and genetic disorders. He also joined the board of Bioclinica (Nasdaq: BIOC), which provides imaging modalities for clinical trials (Bioclinica merged in 2021 to become Clario, a private company). Most recently, he joined the boards of two private companies that are commercializing exciting advances in treatments for conditions caused by protein misfolding (Plex Pharmaceuticals) and in wavelength filtering polymers for contact lenses (Coloursmith Labs). He also joined the Tufts University Graduate School of Biomedical Sciences advisory board, a program that engages stakeholders from science, private equity and governmental sectors to commercialize advances in medicine.

Dr. Rubenstein earned his Bachelor of Arts degree from Cornell University and his medical degree from the Tufts University School of Medicine.

On behalf of the Board of Directors, Visioneering's Chairman, Dr. David J. Mazzo, said, "Dr. Rubenstein is an expert advisor in many areas, particularly in the contact lens industry. We welcome Allan to the VTI Board of Directors and expect that his combination of board expertise, entrepreneurship, business development experience, and industry relationships will help VTI continue to advance its operations as a global force in vision care and myopia management."

Ms. Zita Peach will retire on 18 August 2022, subsequent to the next scheduled quarterly meeting of the Board of Directors. She has served as an independent non-executive director of VTI since February 2017, including as Chair of the Nomination and Remuneration Committee and as a member of the Audit and Risk Committee.

Dr. Mazzo said, "On behalf of the Board, I thank Zita for her service to VTI. Zita joined the Board prior to the Company's initial public offering in 2017 and has provided invaluable insights regarding operations management and best practices for ASX-listed companies. She has gracefully volunteered to remain on the Board until the next meeting as Allan completes his onboarding process."

Ends.

This release was authorized by the COO & CFO, Brian Lane

<i>Company</i>	<i>Investor and media relations</i>
Brian Lane CFO & COO, Visioneering Technologies, Inc. Email: blane@vtivision.com	Haley Chartres HACK Tel: +61 423 139 163 Email: haley@hck.digital

About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Multifocal 1-Day Contact Lens, an extended depth of focus lens that is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit www.vtvision.com.

Foreign ownership restrictions

VTI's CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, plans and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.